- Home
- CAPR vs ASA Comparison
CAPR vs ASA Comparison
Compare CAPR & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- ASA
- Stock Information
- Founded
- CAPR 2005
- ASA 1958
- Country
- CAPR United States
- ASA United States
- Employees
- CAPR N/A
- ASA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- ASA Precious Metals
- Sector
- CAPR Health Care
- ASA Industrials
- Exchange
- CAPR Nasdaq
- ASA Nasdaq
- Market Cap
- CAPR 600.7M
- ASA 549.0M
- IPO Year
- CAPR N/A
- ASA N/A
- Fundamental
- Price
- CAPR $11.15
- ASA $33.50
- Analyst Decision
- CAPR Strong Buy
- ASA
- Analyst Count
- CAPR 6
- ASA 0
- Target Price
- CAPR $41.67
- ASA N/A
- AVG Volume (30 Days)
- CAPR 3.3M
- ASA 59.2K
- Earning Date
- CAPR 05-13-2025
- ASA 06-17-2025
- Dividend Yield
- CAPR N/A
- ASA 0.15%
- EPS Growth
- CAPR N/A
- ASA N/A
- EPS
- CAPR N/A
- ASA 11.67
- Revenue
- CAPR $17,363,588.00
- ASA $3,557,386.00
- Revenue This Year
- CAPR $78.79
- ASA N/A
- Revenue Next Year
- CAPR $158.07
- ASA N/A
- P/E Ratio
- CAPR N/A
- ASA $2.88
- Revenue Growth
- CAPR N/A
- ASA 45.39
- 52 Week Low
- CAPR $3.52
- ASA $16.97
- 52 Week High
- CAPR $23.40
- ASA $34.19
- Technical
- Relative Strength Index (RSI)
- CAPR 56.47
- ASA 69.03
- Support Level
- CAPR $10.04
- ASA $31.24
- Resistance Level
- CAPR $10.80
- ASA $34.19
- Average True Range (ATR)
- CAPR 1.07
- ASA 0.79
- MACD
- CAPR 0.20
- ASA 0.35
- Stochastic Oscillator
- CAPR 87.16
- ASA 88.84
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.